Close

Dyax Corp (DYAX) Annoucns Receipt of FDA Breakthrough Therapy Designation for DX-2930 as HAE Treatment

July 7, 2015 7:16 AM EDT Send to a Friend
Dyax Corp (NASDAQ: DYAX) announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for the investigation ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login